TY - JOUR
T1 - Predictive value of abbreviated olfactory tests in prodromal Parkinson disease
AU - the PARS Investigators
AU - Vaswani, Pavan A.
AU - Morley, James F.
AU - Jennings, Danna
AU - Siderowf, Andrew
AU - Marek, Kenneth
AU - Seibyl, John
AU - Stern, Matthew
AU - Russell, David
AU - Sethi, Kapil
AU - Frank, Samuel
AU - Simuni, Tanya
AU - Hauser, Robert
AU - Ravina, Bernard
AU - Richards, Irene
AU - Liang, Grace
AU - Adler, Charles
AU - Saunders-Pullman, Rachel
AU - Evatt, Marian L.
AU - Lai, Eugene
AU - Subramanian, Indu
AU - Hogarth, Penelope
AU - Chung, Kathryn
N1 - Funding Information:
The authors declare no competing interests. P.A.V. has received grant funding from the Edmond J. Safra Foundation and Michael J. Fox Foundation and has been a consultant to Abbvie. J.F.M. has received grant support from the Department of Defense. D.J. is an employee of Denali Therapeutics, Inc. A.S. has been a consultant to the following companies: Biogen, Prilenia Therapeutics, Wave, Praxis Therapeutics, Alector, Merck and Prevail. He has received grant funding from the Michael J. Fox Foundation and NINDS. K.M. has been a consultant for Invicro, Sanofi, Biohaven, Takeda, Alkahest, Denali, Astellas, Bial, Pfizer, GE Healthcare, Lilly, Calico, Biomx, Neuramedy, Roche and the Michael J Fox Foundation.
Funding Information:
Support for this study is provided by the Department of Defense award number W81XWH-06-067. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.
Publisher Copyright:
© 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2023/6/29
Y1 - 2023/6/29
N2 - There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed “PD-specific” subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10–12 item tests, may have utility for ease of use and cost, but not for superior predictive value.
AB - There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed “PD-specific” subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10–12 item tests, may have utility for ease of use and cost, but not for superior predictive value.
UR - http://www.scopus.com/inward/record.url?scp=85163799521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163799521&partnerID=8YFLogxK
U2 - 10.1038/s41531-023-00530-z
DO - 10.1038/s41531-023-00530-z
M3 - Article
C2 - 37386033
AN - SCOPUS:85163799521
VL - 9
SP - 103
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
SN - 2373-8057
IS - 1
M1 - 103
ER -